R116301

Known as: R 116301 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2009
01219992009

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Purpose: NK1 receptors have been implicated in various neuropsychiatric and other disorders. R116301 is a selective NK1 receptor… (More)
  • figure 1
  • table 1
Is this relevant?
2009
2009
NK1 receptors have been implicated in various neuropsychiatric and other disorders. R116301 is a selective NK1 receptor… (More)
  • figure 1
  • table 1
Is this relevant?
2006
2006
Research on mechanisms of drug action, and preclinical screening of molecules with a potential activity on neuropathic pain… (More)
Is this relevant?
2005
2005
Activation of vanilloid receptors has commonly been used to facilitate neurogenic inflammation and plasma exudation to model… (More)
Is this relevant?
2004
2004
Mu-, kappa- and delta-opioid receptor agonists are reported to attenuate the acetic-acid-induced abdominal constriction response… (More)
Is this relevant?
2003
2003
Substance P (SP) acts as a transmitter of nociception in both the peripheral and the central nervous system. Because the NK-1… (More)
Is this relevant?
2002
2002
In comparison with a series of reference compounds, (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4… (More)
Is this relevant?
2001
2001
The recent development of selective NK(1) receptor antagonists that are active in vivo provides an important research tool to… (More)
Is this relevant?
1999
1999
OBJECTIVE To test the effect of the neurokinin-1 receptor antagonist hydroxybutanedioate (R116301) in human hand veins in vivo… (More)
Is this relevant?